Tumour specificity was demonstrated using an anti-folate receptor 1 (FOLR1) T-cell bispecific antibody engineered with an anti-idiotypic anti-CD3 ‘mask’ joined to an anti-CD3 Fab region via a protease-cleavable linker. This evidence concerns the gene FOLR1 and neoplasm.